Overview

Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body

Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The experiment adopts a single center, randomized, open, single dose, two cycle, and double crossover design. The subjects were randomly divided into TR and RT groups. In the first cycle, they received the test or control formulation on an empty stomach or after a meal. After a cleaning period, they entered the second cycle and received the control or test formulation in the same state. The cleaning period between the two cycles was 7 days.
Phase:
Phase 1
Details
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Treatments:
Amisulpride